# 1. Financial Performance ## A. Key Figures * **Gross Revenue:** **₹2,664 Cr** Q4 (+10% YoY, +2% QoQ) · **₹10,538 Cr** FY26 (+16% YoY) * **Operating EBITDA:** **₹682 Cr** Q4 (+8% YoY, +5% QoQ) · **₹2,638 Cr** FY26 (+14% YoY) * **EBITDA Margin:** **26.8%** Q4 · **26.2%** FY26 * **Profit After Tax (PAT):** **₹387 Cr** Q4 (+3% YoY) · **₹1,631 Cr** FY26 (+22% YoY) * **Leverage & Returns:** **<1.0x** Net Debt/EBITDA · **₹72 Lakhs** EBITDA per bed ## B. Revenue Growth * **Sustained Momentum:** Achieved a landmark **22nd consecutive quarter** of YoY growth, underpinned by consistent scaling across the network. * **Capacity Expansion:** Initiated phased commissioning of approximately **20% additional brownfield capacity** to support long-term volume growth. * **Regulatory & Portfolio Headwinds:** Discontinuation of specific chemotherapy drug billing is projected to reduce annual top-line by **₹200 Cr**, with a **₹130 Cr** impact already realized. ## C. Margins & Profitability * **Operational Resilience:** Maintained robust double-digit margins despite a **30% mandatory discount** on high-value drugs and the loss of associated **15-16%** drug margins. * **Facility Ramp-up:** The Dwarka facility demonstrated significant operational improvement, with losses narrowing from **₹35 Cr** in the first half to under **₹10 Cr** by year-end. * **Cost Dynamics:** Rising doctor talent costs due to micro-market competition are expected to be offset by operating leverage and patient pass-throughs, defending long-term PAT margins of **10-12%**. * **Policy Tailwinds:** The CGHS price revision provided a net financial tailwind of **₹140 Cr**, factoring in a **₹200 Cr** gross benefit offset by GST impacts. ## D. Balance Sheet & Cash Flow * **Deleveraging:** Net debt saw a sequential reduction, supported by strong cash generation and disciplined capital allocation. * **Capital Reinvestment:** Generated **₹1,541 Cr** in annual free cash flow, aggressively deployed toward expansion, upgrades, and strategic land acquisitions in **Vaishali**. * **Shareholder Returns:** Balanced growth investments with capital return, allocating **₹146 Cr** toward dividend payments. --- # 2. Capacity & Infrastructure ## A. Key Figures * **Operational Bed Capacity:** **+8%** Increase · **+20%** Phased brownfield rollout underway * **Utilization:** **80-85%** Dwarka facility · **75%** Noida network-level target * **New Project Investment:** **₹1,400 Cr** Lucknow greenfield (700 beds) * **Project Timelines:** **26-27 months** Smart facility (vs. 36-month industry standard) ## B. Brownfield Commissioning * **Accelerated Rollout:** Phased commissioning is active across Mohali, Mumbai, and Delhi, with full operationality of the current **1,000-bed** phase expected within **2-3 months**. * **Operating Leverage:** New capacity is already EBITDA positive; management anticipates margin accretion over the next two quarters as occupancy scales across new towers. * **Strategic Expansion:** High utilization at Dwarka and Lucknow has triggered secondary expansion plans, including a new oncology center and potential long-term scaling to **2,000 beds** in Gomti Nagar. ## C. Greenfield Projects * **NCR Expansion:** A new **500-bed** Gurgaon facility is slated for year-end commissioning, utilizing a tactical ramp-up starting with **200 beds** to ensure break-even before full scaling. * **Long-term Pipeline:** Strategic projects in Nagpur (**100 beds**) and Zirakpur (**400 beds**) remain on track for **FY28**, while Patparganj is scheduled for **FY29**. * **Regional Hubs:** The Board-approved Lucknow project on Shaheed Path provides a **3-year** horizon to add significant scale to the North India market, with ultimate potential for **900 beds**. ## D. Expansion Timeline & Execution * **Execution Headwinds:** The Gurugram site completion shifted to **H2 end** due to transitory labor shortages and external disruptions (e.g., pollution-related shutdowns and LPG availability). * **Phased Delivery Model:** Management continues to prioritize floor-by-floor openings to optimize immediate demand capture and minimize the gestation period for new capital expenditure. * **Regulatory Status:** No major regulatory bottlenecks are reported for the **2028** pipeline, though Vaishali remains pending building plan approvals. --- # 3. Operating Metrics ## A. Key Figures * **ARPOB:** **INR 77,900** per quarter * **EBITDA per Bed:** **INR 73 Lakh** annualized (vs. INR 74 Lakh Q4 FY25) * **Occupied Bed Days (OBDs):** **+8%** YoY · **+4%** QoQ * **Digital Revenue:** **INR 838 Cr** (31% of overall revenue) * **Web Traffic:** **90 Lakh+** sessions (+39% YoY) ## B. ARPOB & Efficiency Trends * **Metric Compression:** Average Revenue Per Occupied Bed was impacted by a temporary rise in length of stay and the strategic discontinuation of specific high-value institutional chemotherapy drugs. * **Capacity Dynamics:** New bed commissioning has led to higher reported occupancy but lower ARPOB efficiency; management is also shifting specialties like oncology to new towers, altering historical bed productivity patterns. * **Profitability Benchmarks:** While break-even occurs at **50-55%** occupancy, management anticipates a "hockey stick" margin expansion as utilization scales from **60% toward 80%**. ## C. Patient Volume & Length of Stay * **Utilization Growth:** Robust year-on-year and sequential growth in occupied bed days reflects strong underlying demand across the network. * **ALOS Expansion:** Average Length of Stay saw a high single-digit percentage increase, a temporary byproduct of the simultaneous multi-location capacity rollout. * **Oncology Shift:** Despite the revenue impact of drug changes, bed occupancy remains stable as these treatments are daycare-based; however, oncology-specific OBDs declined by **6%**. ## D. Digital & Market Positioning * **Digital Ecosystem:** Significant top-line contribution from digital channels, supported by aggressive growth in web traffic and lead management systems. * **Patient Migration:** Following drug policy changes, some OPD patients are likely migrating to the disorganized sector or smaller nursing homes. --- # 4. Segment & Geography Mix ## A. Key Figures * **International Patient Revenue:** **₹227 Cr** (+12% YoY) · **9%** of total hospital revenue * **Max@Home Revenue:** **₹73 Cr** (+30% YoY) ## B. Oncology Performance * **Strategic Portfolio Rebalancing:** Core revenue (ex-oncology) grew by **15%**, while the oncology share contracted following the deliberate discontinuation of negative-margin chemotherapy drugs. * **Capacity Optimization:** Management expects oncology contribution to stabilize at current lower levels, with other medical specialties projected to absorb the capacity freed by the decline in oncology Occupied Bed Days. ## C. Regional Clusters * **Noida Recovery:** The Noida unit achieved significant operational turnaround with occupancy reaching **64-65%** and robust EBITDA growth following strategic clinical hires. * **Lucknow Expansion Strategy:** Max is leveraging a substantial **32-acre** combined land bank to build a multi-location cluster; management anticipates these sites will be complementary despite their **14km** proximity. ## D. Subsidiary Services * **Ancillary Growth Momentum:** Strong double-digit top-line expansion in homecare and diagnostics, with Max@Home now operating across **16 service lines** and Max Lab serving **6 lakh** patients. --- # 5. M&A & Strategic Initiatives ## A. Key Figures * **Kalinga Hospital (Bhubaneswar):** **250-bed** facility · **10-acre** land parcel · **Majority/Controlling** stake * **Acquisition Profitability:** **₹10 Cr** EBITDA (Kalinga) · **5x** EBITDA growth (Lucknow unit vs. acquisition date) ## B. Asset Integration & Performance * **Strategic Consolidation:** Integration of the Bhubaneswar asset begins in **Q1**, with plans to revamp and expand the facility to leverage existing clinical programs. * **De-risked Portfolio:** Recent acquisitions have maintained positive EBITDA post-integration, eliminating start-up loss risks even after streamlining business practices. * **Future Pipeline:** FY27 priorities center on scaling recently commissioned capacities and advancing the **Sector-56 Gurgaon** hospital project. ## C. Talent Acquisition & Operational Model * **Operating Leverage:** Clinical and non-clinical staffing is complete for new capacities, with significant margin expansion expected as facilities ramp up. * **Clinical Scalability:** Deployment of a "dual-location" model utilizes multiple sets of senior clinicians to prevent operational bottlenecks, replicating a proven Delhi strategy. ## D. Market Entry & Expansion Strategy * **Eastern India Entry:** The Kalinga Hospital acquisition establishes a strategic foothold in Bhubaneswar with significant land for future development. * **Lucknow Hub Development:** Management is optimizing its expansion strategy in Lucknow, utilizing a substantial land bank acquired through the Sahara Hospital deal and **Shaheed Path** land holdings. --- # 6. Regulatory & Operational Risks ## A. Key Figures * **Pending Super-Specialty Upside:** **₹30-40 Cr** annual potential * 5-6% reduction in Occupied Bed Days (OBD) · No OPD impact stated ## B. CGHS Policy & Institutional Headwinds * **Phased Benefit Realization:** Most rate revision gains flowed through in Q4, with the remaining tailwind from super-specialty rates expected to phase in over coming months as more hospitals secure approvals. * **Regulatory Pricing Pressure:** New Delhi mandates require a steep discount on medicines for health schemes; hospitals must provide chemotherapy drugs at these rates or direct patients to government dispensaries. * **Accessibility & Policy Friction:** Significant patient dissatisfaction and treatment disruptions—particularly for ECHS and PSU patients lacking dedicated dispensaries—have led to management's expectation of a potential policy reversal or reconsideration. * **Strategic Offsets:** Management anticipates that the financial gains from the first CGHS price revision in **14 years** will largely offset the revenue lost from drug discontinuations. ## C. Drug Discontinuation & Oncology Impact * **Margin Protection Measures:** The company is discontinuing certain high-value oncology drugs (e.g., Keytruda) where margins fall below the mandated discount threshold to avoid loss-making transactions. * **Industry-Wide Phenomenon:** While the shift in chemotherapy procurement is a sector-wide issue, Max Healthcare faces a pronounced impact due to its high concentration of oncology and institutional business. * **Clinical Implications:** Although the full volume impact was reflected in Q4, management noted that clinical alternatives to restricted drugs may lack the efficacy of preferred branded treatments, leading to patient complaints. ## D. Labor & Project Execution * **Project Continuity Incentives:** To mitigate regional labor shortages and ensure progress at the Gurugram site, the company is providing on-site meals to a workforce of **1,100–1,200** contract laborers. * **Phased Manpower Scaling:** Hiring for new acquisitions and the **Bhubaneswar** facility is being managed in stages to control costs and navigate competitive labor markets. --- # 7. Guidance & Outlook ## A. Growth Levers * **Revenue Drivers:** Future top-line expansion is structurally anchored by steady ARPOB appreciation and increasing Occupied Bed Days (OBDs). ## B. Breakeven Targets * **Greenfield Execution:** Management targets operational breakeven for the Gurugram project within **FY28**, citing high confidence following the accelerated ramp-up of the Dwarka facility.